TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CytoDyn ( (CYDY) ) has provided an announcement.
On November 21, 2025, CytoDyn Inc. held its Annual Meeting of Stockholders, where several key decisions were made. The stockholders elected the company’s director nominees to serve until the 2026 annual meeting and approved CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending May 31, 2026. Additionally, stockholders approved the compensation of named executive officers and voted to hold an advisory vote on executive compensation annually. A significant decision was the approval to amend the company’s certificate of incorporation to increase the total number of authorized shares of common stock from 1.75 billion to 2.25 billion shares, potentially impacting the company’s financial strategy and market operations.
More about CytoDyn
CytoDyn Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for multiple therapeutic indications. The company primarily develops treatments for HIV, cancer, and other immune-related diseases.
Average Trading Volume: 1,985,227
Technical Sentiment Signal: Buy
Current Market Cap: $373.6M
Find detailed analytics on CYDY stock on TipRanks’ Stock Analysis page.